Identification Of Novel Combination Therapies Active In Bcl2 Inhibitor-Resistant Patient-Derived Aml Models
BLOOD(2019)
摘要
Acute myeloid leukemia (AML) is an aggressive, heterogeneous malignancy. AML patients whose disease relapses on chemotherapy or are unfit for aggressive induction regimens have limited therapeutic options. Many patients benefit from the combination of venetoclax (BCL2i) and a hypomethylating agent (HMA) but this regimen is rarely curative. The addition of novel agents could provide improved benefit for relapsed/refractory patients.
更多查看译文
关键词
aml,inhibitor-resistant,patient-derived
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要